OnDemand Complicated Cataracts Cases: A Multi-Disciplinary Approach 2025

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

This conference will offer a deep dive into complicated cataract cases and their intersection with other ophthalmology specialties, specifically cornea, glaucoma, and retina.

1. Evaluate surgical options cataract cases with other ocular comorbidities
2. Implement the use of new technologies and devices in cataract care
3. Strategize lens options and care plans for patients with abnormal biometry but who want glasses independence
4. Educate care providers on management of postoperative complications

Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 3.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 3.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

John C Anhalt, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Ayan Chatterjee, MD
Kremer Eye and Wills Eye

Faculty

Honoraria-Alcon (Relationship has ended)

Jordan Deaner, MD
Mid Atlantic Retina, Wills Eye Hospital

Faculty

Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Alimera Sciences (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Regeneron (Relationship has ended)

Brad H Feldman, MD
Philadelphia Eye Associates

Faculty

Nothing to disclose

Colleen Halfpenny, MD
Wills

Faculty

Nothing to disclose

Anton Orlin, MD
Weill Cornell Medical College

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended)

Ravi Patel, MD, MBA
Wills Eye Hospital

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan|Consulting Fee-Oyster Point Pharmaceuticals|Consulting Fee-Bio-Tissue|Consulting Fee-Johnson & Johnson|Consulting Fee-Bausch + Lomb|Speakers Bureau-Alcon|Speakers Bureau-Tarsus|Speakers Bureau-Lenz Therapeutics|Speakers Bureau-Glaukos Corporation

Mark F Pyfer, MD
Northern Ophthalmic Associates

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson|Paid consultant-Johnson & Johnson|Independent Contractor (included contracted research)-Sight Sciences (Relationship has ended)|Speakers Bureau-Sight Sciences|Speakers Bureau-Rayner Surgical|Independent Contractor (included contracted research)-Tarsus (Relationship has ended)

Reza Razeghinejad, MD
WEH

Faculty

Grant or research support-Olleyes

Richard Tipperman, MD
--None--

Faculty

Advisor-Alcon

Alice Williams, MD
Friedberg Eye Associates

Faculty

Nothing to disclose

Alessandra K Intili, MD
Valley Eye Professionals

Faculty, Planner

Nothing to disclose

Melissa Sieber, MD
Ophthalmic Associates

Faculty, Planner

Nothing to disclose

Brett Weinstock, MD
Friedberg Eye Associates

Faculty, Planner

Nothing to disclose